AAV with ALB(1.4) promoter driven CreERT2
This AAV expresses CreERT2 driven by a liver ALB(1.4) promoter.
The ALB(1.4) is a shorter version of the ALB(1.7) promoter with a total length of 1.4 Kb. In mouse liver cells, the transgene expression from this ALB(1.4) synthetic promoter is about 3 times lower than that of ALB(1.7) promoter but 10-100 fold greater than that of the CMV promoter 10-20 weeks after plasmid injection into mouse liver.
A mutated form of estrogen ligand-binding domain (ERT2) that binds to synthetic antagonists (such as tamoxifen or its derivative 4-hydroxy-tamoxifen) but not to circulating estrogen, was fused to the Cre recombinase (Cre) to create CreERT2 (also known as “inducible Cre”). When tamoxifen binds to CreERT2, it induces a conformational change of CreERT2, leading to its nuclear translocation, followed by Cre/Lox-mediated recombination.
Ready-to-use AAV expressing CreERT2 driven by a liver ALB(1.4) promoter. Available in AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAV-DJ and other serotypes.